Harmony Biosciences Holdings, Inc.HRMYNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank44
5Y CAGR+3.2%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
+3.2%/yr
Long-term compound
Percentile
P44
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 16.02% |
| Q3 2025 | 37.07% |
| Q2 2025 | 133.40% |
| Q1 2025 | -55.02% |
| Q4 2024 | 7.18% |
| Q3 2024 | 65.43% |
| Q2 2024 | 36.85% |
| Q1 2024 | -59.38% |
| Q4 2023 | 21.50% |
| Q3 2023 | 70.25% |
| Q2 2023 | -12.91% |
| Q1 2023 | 59.53% |
| Q4 2022 | -51.67% |
| Q3 2022 | 63.66% |
| Q2 2022 | 16.91% |
| Q1 2022 | -23.13% |
| Q4 2021 | 23.37% |
| Q3 2021 | 68.37% |
| Q2 2021 | 44.21% |
| Q1 2021 | 24.71% |
| Q4 2020 | 13.68% |
| Q3 2020 | 82.91% |
| Q2 2020 | 118.10% |
| Q1 2020 | -11.32% |
| Q4 2019 | -2.28% |
| Q3 2019 | -34.78% |
| Q2 2019 | -64.24% |
| Q1 2019 | 0.00% |